Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,768 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Then Placebo Clear all
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 13, 2026, 4:44 AM EDT
Recruiting Phase 1 Interventional

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

NCT03973268
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Major Depression
Interventions
Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
Device · Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

NCT02683785
View directory record Official record
Conditions
Osteoarthritis
Interventions
GSK3196165, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 13, 2026, 4:44 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Suspended Not applicable Interventional

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

NCT04419779
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

NCT03943056
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 13, 2026, 4:44 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AIDS 347: IL-6 Blockade in Treated HIV Infection

NCT02049437
View directory record Official record
Conditions
HIV Infections
Interventions
tocilizumab, Placebo
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

NCT01207453
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
24 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Mitochondria and Chronic Kidney Disease

NCT03177798
View directory record Official record
Conditions
Hemodialysis-Induced Symptom, Mitochondrial Diseases
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 78 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

NCT03162796
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 13, 2026, 4:44 AM EDT
Recruiting Phase 2Phase 3 Interventional

4-aminopyridine Treatment for Nerve Injury

NCT03701581
View directory record Official record
Conditions
Nerve Injury, Prostate Cancer
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

NCT00046930
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
91
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 13, 2026, 4:44 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Topical Cannabidiol Cream and Post-exercise Recovery

NCT05044936
View directory record Official record
Conditions
Muscle Damage
Interventions
Cannabidiol Oil, Resistance Exercise
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 13, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
LCQ908, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 13, 2026, 4:44 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 13, 2026, 4:44 AM EDT